Articles tagged "FK506"

2020 American Transplant Congress
Assessment of Time to Therapeutic Tacrolimus Levels Following Renal Transplantation in a Non-Weight-Based Dosing Model
J. Banbury¹, A. Dodson¹, C. Lin², K. Gutierrez¹
¹University of Alabama at Birmingham Hospital, Birmingham, AL, ²Center for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, AL
*Purpose: The optimal initial dose for tacrolimus (TAC) after renal transplant (RT) remains controversial with limited evidence comparing weight-based and conservative strategies. Recent literature suggests…
2020 American Transplant Congress
Early Calculation of the Tacrolimus Concentration-to-Dose Ratio Does Not Predict Outcomes after Renal Transplantation
K. Schütte-Nütgen, I. Bartmann, B. Suwelack, S. Reuter
Department of Internal Medicine D, University Hospital Münster, Münster, Germany
*Purpose: There is emerging interest in the concentration-to-dose (C/D) ratio of tacrolimus (Tac) as it is linked to outcomes after renal transplantation (RTx). Recently, we…
2020 American Transplant Congress
Clinical Implications of Tacrolimus Time in Therapeutic Range in Urban Renal Transplant Recipients Under an Early Corticosteroid Withdrawal Protocol
D. Pierce, P. West-Thielke, Z. Hajjiri, S. Gaitonde, I. Tzvetanov, E. Benedetti, A. Lichvar
University of Illinois at Chicago, Chicago, IL
*Purpose: Tacrolimus displays wide inter- and intra-patient variability, necessitating therapeutic drug monitoring. Assessing the duration of time in therapeutic range (TTR) is an additional tool…
2020 American Transplant Congress
Specific Gut Microbiota Community Suppresses Acute Rejection by Reducing Natural Killer Cell Population
W. Zhang, L. Gong, Y. Xu, X. Hu
Department of Urology, Capital Medical University Beijing Chaoyang Hospital, Urology Institute of Capital Medical University, Beijing, China
*Purpose: The gut microbiota community was reported to be altered by high-dose FK506 treatment, while fecal microbiota transplantation with such microbiota plus low-dose FK506 could…
2020 American Transplant Congress
Dosing and Outcomes of Conversion to Extended-Release Tacrolimus in Heart and Lung Transplant Recipients
C. Doligalski¹, K. Walter¹, P. Chang², L. J. Lobo²
¹University of North Carolina Medical Center, Chapel Hill, NC, ²Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
*Purpose: Extended release tacrolimus (LCP-Tac) is a novel once daily formulation with improved pharmacokinetic parameters compared to immediate release tacrolimus (IR-Tac). LCP-Tac use in renal…
2020 American Transplant Congress
Protective Effect of Fucoidan Against Tacrolimus-Induced Nephrotoxicity in LLC-PK1 Cells
H. J. Jang
Surgery, University of Ulsan, Gangneung Asan Hospital, Gangneung, Korea, Republic of
*Purpose: Tacrolimus (FK506) is an immunosuppressant agent that is frequently used to prevent rejection of solid organs upon transplant. However, nephrotoxicity due to apoptosis and…
2020 American Transplant Congress
The Effects of Rivaroxaban and Apixaban on Tacrolimus Pharmacokinetics
A. C. Scheibner¹, C. Franco-Martinez¹, E. Kincaide¹, R. Hall¹, C. Long²
¹Pharmacotherapy Division, College of Pharmacy, The University of Texas at Austin, University Health System, The University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Feik School of Pharmacy, University of the Incarnate Word, University Health System, The University of Texas Health Science Center at San Antonio, San Antonio, TX
*Purpose: To clarify the pharmacokinetic impact of rivaroxaban (RIVA) and apixaban (APIX) on tacrolimus (TAC) concentrations.*Methods: Solid organ transplant recipients 18-years or older who were…
2020 American Transplant Congress
Envarsus XR Use Can Benefit Serum Creatinine Levels in Vascularized Composite Allotransplantation Patients
C. M. Cooney¹, V. Javia¹, J. Littleton¹, D. S. Cooney¹, R. J. Redett¹, J. T. Shores¹, D. C. Brennan², G. Brandacher¹
¹Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Surgery, Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: Vascularized composite allotransplantation (VCA) is a life-enhancing (as opposed to life-saving) procedure. Therefore, minimizing adverse outcomes associated with chronic immunosuppression is vital to determining…
2020 American Transplant Congress
Activation of Tacrolimus Induced Cytotoxicity Through Apoptotic Pathways
S. Chung, S. Choi
Department of Surgery, Chonnam National University, Gwangju, Korea, Republic of
*Purpose: To elucidate the mechanism of cytotoxicity in FK506-treated Jurkat T cells, signal transduction pathway of TNF-related events was studied.*Methods: Viability of Jurkat T cells…
2019 American Transplant Congress
FK506 Influence Glucose Metabolism by Short Chain Fatty Acid
W. Jiao¹, Z. Zhang¹, L. Liu², X. Hu¹
¹Urology, Capital Medical University Beijing Chaoyang Hospital, Beijing, China, ²GI Divison, West China Hospital, Beijing, China
*Purpose: FK506 is one of the most common immunosuppressant drugs in organ transplantation, which have been demonstrated to cause glucose metabolism disorder and alterd the…